113 related articles for article (PubMed ID: 32829355)
1. [Efficacy of Amrubicin Monotherapy for Patients with Extrapulmonary Neuroendocrine Carcinomas Refractory to Platinum-Based Chemotherapy].
Funasaka C; Kanemasa Y; Kageyama A; Shimoyama T; Omuro Y
Gan To Kagaku Ryoho; 2020 Aug; 47(8):1205-1208. PubMed ID: 32829355
[TBL] [Abstract][Full Text] [Related]
2. Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy.
Nio K; Arita S; Isobe T; Kusaba H; Kohashi K; Kajitani T; Tamura S; Hirano G; Mitsugi K; Makiyama A; Esaki T; Ariyama H; Oda Y; Akashi K; Baba E
Cancer Chemother Pharmacol; 2015 Apr; 75(4):829-35. PubMed ID: 25702050
[TBL] [Abstract][Full Text] [Related]
3. Amrubicin Monotherapy for Patients with Platinum-Pretreated Non-Gastrointestinal Non-Pancreatic Extrapulmonary Neuroendocrine Carcinoma.
Ebata T; Shimoi T; Ishiwata T; Iwasawa S; Bun S; Yunokawa M; Yonemori K; Takiguchi Y; Tamura K
Oncology; 2017; 93(3):177-182. PubMed ID: 28521313
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of temozolomide monotherapy in patients with extrapulmonary neuroendocrine carcinoma.
Kobayashi N; Takeda Y; Okubo N; Suzuki A; Tokuhisa M; Hiroshima Y; Ichikawa Y
Cancer Sci; 2021 May; 112(5):1936-1942. PubMed ID: 33453146
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
Igawa S; Shirasawa M; Fukui T; Nishinarita N; Sone H; Ozawa T; Sugita K; Okuma Y; Kurahayashi S; Ono T; Sugimoto A; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
Oncology; 2018; 94(4):207-214. PubMed ID: 29393275
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of amrubicin monotherapy in patients with platinum-refractory metastatic neuroendocrine carcinoma of the gastrointestinal tract: a single cancer center retrospective study.
Kitagawa Y; Osumi H; Shinozaki E; Ota Y; Nakayama I; Suzuki T; Wakatsuki T; Ichimura T; Ogura M; Ooki A; Takahari D; Suenaga M; Chin K; Yamaguchi K
Cancer Manag Res; 2019; 11():5757-5764. PubMed ID: 31417315
[TBL] [Abstract][Full Text] [Related]
7. Amrubicin in patients with platinum-refractory metastatic neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the gastrointestinal tract.
Araki T; Takashima A; Hamaguchi T; Honma Y; Iwasa S; Okita N; Kato K; Yamada Y; Hashimoto H; Taniguchi H; Kushima R; Nakao K; Boku N; Shimada Y
Anticancer Drugs; 2016 Sep; 27(8):794-9. PubMed ID: 27341105
[TBL] [Abstract][Full Text] [Related]
8. Clinical Analysis of Extrapulmonary Neuroendocrine Carcinoma: A Retrospective and Single Institution Experience.
Okumura T; Noguchi T; Sekiguchi N; Kobayashi T; Kanda S; Ida K; Minagawa T; Tokumaru S; Umemura T; Koizumi T
Chemotherapy; 2023; 68(2):87-94. PubMed ID: 36327945
[TBL] [Abstract][Full Text] [Related]
9. A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients.
Imai H; Sugiyama T; Tamura T; Minemura H; Kaira K; Kanazawa K; Yokouchi H; Kasai T; Kaburagi T; Minato K;
Cancer Chemother Pharmacol; 2017 Sep; 80(3):615-622. PubMed ID: 28761968
[TBL] [Abstract][Full Text] [Related]
10. Amrubicin as second-line and beyond treatment for platinum-refractory advanced thymic carcinoma.
Hirai F; Seto T; Yamanaka T; Toyozawa R; Inamasu E; Kojo M; Toyokawa G; Morodomi Y; Shiraishi Y; Takenaka T; Yamaguchi M; Takenoyama M; Ichinose Y
Jpn J Clin Oncol; 2013 Oct; 43(10):1018-22. PubMed ID: 23917962
[TBL] [Abstract][Full Text] [Related]
11. Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine Carcinoma.
Ando T; Hosokawa A; Yoshita H; Ueda A; Kajiura S; Mihara H; Nanjo S; Fujinami H; Nishikawa J; Ogawa K; Nakajima T; Imura J; Sugiyama T
Gastroenterol Res Pract; 2015; 2015():425876. PubMed ID: 26199623
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcome of amrubicin therapy according to the prior chemotherapy sensitivities of extensive small cell lung cancer.
Mitsuoka S; Kudoh S; Kimura T; Yoshimura N; Tanaka H; Suzumura T; Umekawa K; Nagata M; Ueda T; Hirata K
Osaka City Med J; 2011 Dec; 57(2):59-66. PubMed ID: 22443079
[TBL] [Abstract][Full Text] [Related]
13. Amrubicin monotherapy for elderly patients with previously treated lung cancer.
Nakao M; Oguri T; Suzuki T; Kunii E; Tomita Y; Iwashima Y; Miyazaki M; Maeno K; Sato S; Ueda R
Intern Med; 2010; 49(17):1857-62. PubMed ID: 20823645
[TBL] [Abstract][Full Text] [Related]
14. [Retrospective analysis of amrubicin hydrochloride monotherapy in patients with previously treated small-cell lung cancer].
Nitta T; Yamasaki M; Kajihara T; Mito A; Awaya H; Ikegami Y; Arita K
Gan To Kagaku Ryoho; 2010 Jun; 37(6):1045-9. PubMed ID: 20567105
[TBL] [Abstract][Full Text] [Related]
15. Amrubicin monotherapy for elderly patients with relapsed extensive-disease small-cell lung cancer: A retrospective study.
Sone H; Igawa S; Kasajima M; Ishihara M; Hiyoshi Y; Hosotani S; Ohe S; Ito H; Kaizuka N; Manaka H; Fukui T; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
Thorac Cancer; 2018 Oct; 9(10):1279-1284. PubMed ID: 30126051
[TBL] [Abstract][Full Text] [Related]
16. Amrubicin for the treatment of neuroendocrine carcinoma of the gastrointestinal tract: a retrospective analysis of five cases.
Asayama M; Fuse N; Yoshino T; Yano T; Tahara M; Doi T; Fujii S; Ohtsu A
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1325-30. PubMed ID: 21461890
[TBL] [Abstract][Full Text] [Related]
17. Expression of ERCC1, Bcl-2, Lin28a, and Ki-67 as biomarkers of response to first-line platinum-based chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinomas or small cell lung cancer.
de M Rêgo JF; de Medeiros RSS; Braghiroli MI; Galvão B; Neto JEB; Munhoz RR; Guerra J; Nonogaki S; Kimura L; Pfiffer TE; de Castro G; Hoff PM; Filho DR; Costa FP; Riechelmann RP
Ecancermedicalscience; 2017; 11():767. PubMed ID: 28955403
[TBL] [Abstract][Full Text] [Related]
18. A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901).
Murakami H; Yamamoto N; Shibata T; Takeda K; Ichinose Y; Ohe Y; Yamamoto N; Takeda Y; Kudoh S; Atagi S; Satouchi M; Kiura K; Nogami N; Endo M; Watanabe H; Tamura T
Lung Cancer; 2014 Apr; 84(1):67-72. PubMed ID: 24530204
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the recommended dose and efficacy of amrubicin as second- and third-line chemotherapy for small cell lung cancer.
Igawa S; Yamamoto N; Ueda S; Ono A; Nakamura Y; Tsuya A; Murakami H; Endo M; Takahashi T
J Thorac Oncol; 2007 Aug; 2(8):741-4. PubMed ID: 17762341
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of amrubicin third-line chemotherapy in patients with relapsed extensive-disease small-cell lung cancer: A retrospective and historical study in a single institute.
Sonehara K; Tateishi K; Fukushima T; Komatsu M; Yamamoto H; Koizumi T; Hanaoka M
Thorac Cancer; 2019 Sep; 10(9):1805-1811. PubMed ID: 31350820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
